That puts both men far ahead of Big Pharma chiefs such as Pfizer's ($PFE) Ian Read and Novartis' ($NVS) Joe Jimenez, and even farther ahead of fellow biotech CEOs, including Gilead Sciences' ($GILD) John Martin. Regeneron is well aware of that fact, and it spent many pages in its 2016 proxy statement laying out the company's shareholder returns against its rivals (higher) and its growth in returns compared with executive pay increases (much lower). The board's compensation committee even figured up Schleifer's direct compensation as a percentage of Regeneron's market cap: 0.08%, in case you were wondering, down from 0.20% in 2011.